Skip to content
Home
Team
Healthcare
Patient-First Statement
Pipeline
Invest
Investor Hub
Corporate Governance
Shareholder Communications
News
Contact
Menu
Home
Team
Healthcare
Patient-First Statement
Pipeline
Invest
Investor Hub
Corporate Governance
Shareholder Communications
News
Contact
Sara Polanski
November 21, 2022
Emyria RWE Registry analysis demonstrates safety & efficacy of oral medicinal cannabis
November 9, 2022
Why is Ultra-Pure CBD Key to Sustainable Cannabis-based Treatments?
October 17, 2022
MDMA Webinar recording
October 12, 2022
Emyria & PsychoGenics collaboration in PharmaVoice
October 6, 2022
Upcoming Speaking Engagements for October
September 29, 2022
Emyria featured in The Australian’s biotech Investor Guide
September 27, 2022
Expressions of Interest for EMD-RX5 Phase 3 Clinical Trial now open
September 19, 2022
Emyria commences US preclinical program with PsychoGenics
August 30, 2022
Emyria releases Annual Report
August 18, 2022
Emyria’s Ultra – Pure CBD is a Step Closer to Registration
Load More
Search
Search
Search
ASX News
General News
Publications
Thought Leadership
Uncategorised